Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Sponsor
Chiron Corporation (Industry)
Overall Status
Completed
CT.gov ID
NCT00045864
Collaborator
(none)
33

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.

Condition or Disease Intervention/Treatment Phase
  • Drug: Recombinant Human Interleukin-2 and Rituximab
Phase 2

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion:
    • Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens.
    Exclusion:
    • Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment

    • Clinically significant pulmonary dysfunction.

    • Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment).

    • Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.

    • History of autoimmune disease.

    • History of positive serology for human immunodeficiency virus (HIV).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 ACRC/Arizona Clinical Research Center, Inc. Tucson Arizona United States 85712
    2 Hoag Cancer Center Newport Beach California United States 92658
    3 UC Davis Cancer Center Sacramento California United States 95817
    4 John Wayne Cancer Institute Santa Monica California United States 90404
    5 Stanford University Medical Center Stanford California United States 94305-5151
    6 California Cancer Medical Center West Covina California United States 91790
    7 Georgetown University Medical Center, Lombardi Cancer Center Washington District of Columbia United States 20007
    8 Washington Cancer Institute Washington District of Columbia United States 20010
    9 Division of Hematology/Oncology, University of Miami School of Medicine Miami Florida United States 333136
    10 Northwestern University, Feinberg School of Medicine Chicago Illinois United States 60611
    11 Rush Cancer Institute Chicago Illinois United States 60612
    12 Oncology Specialists, S.C. Park Ridge Illinois United States 60068
    13 Cancer Care Center Bloomington Indiana United States 47403
    14 Consultants in Blood Disorders and Cancer Louisville Kentucky United States 40207
    15 Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology Shreveport Louisiana United States 71130
    16 Kansas City Oncology and Hematology Group Kansas City Missouri United States 64111
    17 Arch Medical Group, LLC St. Louis Missouri United States 63141
    18 Dartmouth-Hitchcock-Medical Center Lebanon New Hampshire United States 03756
    19 Our Lady of Mercy Medical Center, Comprehensive Cancer Center Bronx New York United States 10466
    20 Memorial Sloan Kettering Cancer Center New York New York United States 10021
    21 East Carolina University School of Medicine/ Division of Hematology/Oncology Greenville North Carolina United States 27858
    22 Roger Maris Health System Fargo North Dakota United States 58122
    23 Gabrail Cancer Center Canton Ohio United States 44718
    24 Oncology Hematology Care Inc. Cincinnati Ohio United States 45242
    25 The Cleveland Clinic Foundation Cleveland Ohio United States 44195
    26 Hematology /Oncology Consultants Inc. Columbus Ohio United States 43235
    27 Oregon Heath and Science University Portland Oregon United States 97201
    28 University of Pennsylvania Philadelphia Pennsylvania United States 19104
    29 Cancer Centers of the Carolinas Greenville South Carolina United States 29615
    30 Germantown Cancer Center Germantown Tennessee United States 38138
    31 Vanderbilt University Medical Center Nashville Tennessee United States 37232
    32 Cancer Specialists of South Texas, P.A. Corpus Christi Texas United States 78412
    33 Virginia Cancer Institute Richmond Virginia United States 23230

    Sponsors and Collaborators

    • Chiron Corporation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00045864
    Other Study ID Numbers:
    • IL2NHL05
    First Posted:
    Sep 16, 2002
    Last Update Posted:
    Feb 6, 2006
    Last Verified:
    Feb 1, 2006

    Study Results

    No Results Posted as of Feb 6, 2006